| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 06/06/2007 | CN1973825A Use of magnesium adenosine triphosphate in injection, the injection and its prepn process |
| 06/06/2007 | CN1973681A Technological process of producing oat diet fiber and nutritious powder with oat bran |
| 06/06/2007 | CN1973671A Production process of microwave modified oat fiber powder |
| 06/06/2007 | CN1319984C Cyclovirobuxine extraction and purification method |
| 06/06/2007 | CN1319968C Compositions useful as inhibitors of GSK-3 |
| 06/06/2007 | CN1319963C Dihydrothiaphenanthrenecarbonylguanidines: composition, process of making, and use as medicament or diagnostic aid |
| 06/06/2007 | CN1319959C Polyhydroxystilbenes and stibene oxides as antisoriatic agents and protein kinase inhibitors |
| 06/06/2007 | CN1319956C Thiazolidine diketone derivatives, preparing process and application of pharmaceutical preparations of the same |
| 06/06/2007 | CN1319938C Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance |
| 06/06/2007 | CN1319586C Medicinal composition for treating brain apoplexy |
| 06/06/2007 | CN1319578C Chinese medicine compound preparation, its preparation method and use |
| 06/06/2007 | CN1319557C Chinese medicine composition for treating cardiac and cerebral vascular diseases and its preparation |
| 06/06/2007 | CN1319552C Medicine for curing hypertension and cardio-cerebrovascular diseases by using extract of Chinese medicine material bushy knotweed root as effective component |
| 06/06/2007 | CN1319551C Method for extracting volatile oil and liposoluble alkaloid from plumula nelumbini |
| 06/06/2007 | CN1319550C Preparation of traditional Chinese medicine for treating cardio vascular disease, its preparation method and quality control method |
| 06/06/2007 | CN1319541C Spray agent of dried powder in use for treating hemorrhoid and preparation method |
| 06/06/2007 | CN1319539C Medicinal composition with synergetic function |
| 06/06/2007 | CN1319538C Preparation method of Astragaloside material medicine, the material medicine and preparation |
| 06/06/2007 | CN1319534C Lycopene and coenzyme Q#-[10] containing formulation and its manufacturing method |
| 06/06/2007 | CN1319530C Neurotrophic factor production promoter |
| 06/06/2007 | CN1319528C Combination preparation of the sodium-hydrogen exchange inhibitor cariporide with ACE inhibitors for preventing heart failure |
| 06/06/2007 | CN1319526C Application of soybean isoflavone in the prevention and treatment of anoxic hypertensive pulmonary vascular disease |
| 06/06/2007 | CN1319524C Turmeria oil extract dripping pill, its preparation method and application |
| 06/06/2007 | CN1319521C Composite red sage root granules for cardio-cerebral diseases and its preparing method |
| 06/06/2007 | CN1319519C Composite red sage root spray for cardio-cerebral diseases |
| 06/05/2007 | USRE39681 1-(4-sulfamyaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2 |
| 06/05/2007 | US7227031 Aspirin-triggered lipoxins as modulators of diseases associated with polymorphoneutrophil inflammation; antiinflammatory agents |
| 06/05/2007 | US7227022 Use of 2-amino-thiazoline derivatives as inhibitors of inducible no-synthase |
| 06/05/2007 | US7227020 protein kinase inhibitors; asthma, psoriasis, antiinflammatory agents; inflammatory bowel disorders |
| 06/05/2007 | US7227014 Oligonucleotide with 8-50 bases specifically hybridizes with a nucleic acid molecule encoding human apolipoprotein(a) and inhibits its expression |
| 06/05/2007 | US7226945 Estrogen receptor-β ligands |
| 06/05/2007 | US7226943 Antilipemic agents |
| 06/05/2007 | US7226940 Such as 3-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)-4-methoxybenzylidene-2,4-thiazolidinedione; Hodgkin's disease |
| 06/05/2007 | US7226935 Hypoglycemic agent |
| 06/05/2007 | US7226929 drugs such as 6 -Chloro-N-{(3S)-1-[(1S)-1-methyl-2-oxo-2-piperidin-1-ylethyl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide, used as antithrombotic agents |
| 06/05/2007 | US7226918 DNA-PK inhibitors |
| 06/05/2007 | US7226907 Contacting cardiac muscle cells with a neuregulin protein to activate the MAP kinase pathway in cardiac muscle cells and induce remodeling of cardiac muscle cell sarcomeric and cytoskeleton structures or cell-cell adhesions |
| 06/05/2007 | US7226586 Biocompatible polymer designed to release nitric oxide; extensively cross-linked polyamine-derivatized divinylbenzene; sustained release, potentiation |
| 06/05/2007 | CA2529003A1 Neural crest stem cell and uses thereof |
| 06/05/2007 | CA2411671C Inhibitors of alpha l beta 2 mediated cell adhesion |
| 06/05/2007 | CA2376094C Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor (ppar) .alpha. |
| 06/05/2007 | CA2214431C Human vegf-specific antisense oligonucleotides |
| 05/31/2007 | WO2007062342A1 Heterocyclic cetp inhibitors |
| 05/31/2007 | WO2007061995A2 Biomarkers for statin-induced myopathy or rhabdomyolysis |
| 05/31/2007 | WO2007061803A1 High-potency sweetener composition with c-reactive protein reducing substance and compositions sweetened therewith |
| 05/31/2007 | WO2007061795A1 Natural high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses |
| 05/31/2007 | WO2007061074A1 Novel bisboron compound |
| 05/31/2007 | WO2007061022A1 Mitochondrial function of prohibitin 2 (phb2) |
| 05/31/2007 | WO2007060992A1 Agent for preventing or improving metabolic syndrome or insulin-resistance syndrome |
| 05/31/2007 | WO2007060899A1 Application of actin-binding protein to disease associated with cell motility |
| 05/31/2007 | WO2007060318A1 Novel indolizine derivatives, method for preparing same and therapeutic compositions comprising same |
| 05/31/2007 | WO2007060206A2 Further crystalline forms of rostafuroxin |
| 05/31/2007 | WO2007060132A1 N-hydroxyamide derivatives and use thereof |
| 05/31/2007 | WO2007060028A1 Napthyridine compounds as rock inhibitors |
| 05/31/2007 | WO2007059631A1 Selected dosage for the treatment of cardiovascular and related pathologies |
| 05/31/2007 | WO2007044574A3 Pharmaceutical compositions, methods of preparation thereof, and methods of treatment |
| 05/31/2007 | WO2007042669A3 Derivatives of 4-amino-quinazoline, preparation method thereof and use of same in therapeutics |
| 05/31/2007 | WO2007042660A3 Substituted 1-amino-phthalzine derivatives, preparation and therapeutic use thereof |
| 05/31/2007 | WO2007041077A3 Heterocyclic amide derivatives as rxr agonists for the treatment of dyslipidemia, hypercholesterolemia and diabetes |
| 05/31/2007 | WO2007039254A3 Use of fusion proteins for the prevention or the treatment of pathologies resulting from ischemia |
| 05/31/2007 | WO2007037554A9 Adsorbent for advanced glycation endproducts |
| 05/31/2007 | WO2007037543A9 Biarylamide derivative |
| 05/31/2007 | WO2007016525A3 Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| 05/31/2007 | WO2007014851A3 Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
| 05/31/2007 | WO2007010498A3 Compositions for reducing the incidence of drug induced arrhythmia |
| 05/31/2007 | WO2007003957A3 Steroidal glycoside compounds as core 2 glcnac- t inhibitors |
| 05/31/2007 | WO2006116435A3 Methods of treating atherosclerosis |
| 05/31/2007 | WO2006110496A3 Activation of sodium potassium atpase |
| 05/31/2007 | WO2006078463A3 Method for treating cardiovascular disease |
| 05/31/2007 | WO2006045010A3 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| 05/31/2007 | US20070124837 Desaturase genes, enzymes encoded thereby, and uses thereof |
| 05/31/2007 | US20070124825 Use of hepcidin as a regulator of iron homeostasis |
| 05/31/2007 | US20070123583 Using low dose of a microtubule stabilizing agent such as taxol; prevents artery blockage while minimizing any negative side effects |
| 05/31/2007 | US20070123561 Preparation of 1,7-disubstituted azabensimidazoles as kinase inhibitors |
| 05/31/2007 | US20070123549 platelet activating factor aceylhydrolase inhibitors such as 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5-ethylpyrimidin-4-one; for treatment of atherosclerosis |
| 05/31/2007 | US20070123530 e.g. (2-chloropyrimidin-4-yl)-(4-ethyl-3H-thiazol-2ylidene)-acetonitrile,[4-(4-chlorophenyl)-1,3-thiazol-2(3H)-ylidene](2-chloropyrimidin-4-yl)acetonitrile; Jun N-terminal kinase and Glycogen Synthase Kinase 3 inhibitor; antidiabetic, antiinflammatory, anticarcinogenic agent; neurodegenerative diseases |
| 05/31/2007 | US20070123528 Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity |
| 05/31/2007 | US20070123521 Cinnamoyl derivatives and use thereof |
| 05/31/2007 | US20070123503 Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases |
| 05/31/2007 | US20070123491 Podophyllotoxin derivatives as igf-1r inhibitors |
| 05/31/2007 | US20070122860 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway |
| 05/31/2007 | US20070122451 Biogically non-degradable peptides, angiostensin converting enzyme inhibitor, drug and functional food |
| 05/31/2007 | DE102005057225A1 New 8-beta-substituted estratriene derivatives esterified with a sulfamoylphenyl-substituted acid residue, are prodrugs useful as carboanhydrase inhibitors for treating estrogen deficiency disorders |
| 05/31/2007 | DE102005057224A1 New 9-alpha substituted estratriene derivatives esterified with a sulfamoylphenyl-substituted acid residue, are prodrugs useful as carboanhydrase inhibitors for treating estrogen deficiency disorders |
| 05/31/2007 | DE102005050376A1 Dicarbonsäure-Derivate und ihre Verwendung Dicarboxylic acid derivatives and their use |
| 05/31/2007 | DE102005049954A1 Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen Triazolopyridine derivatives as inhibitors of lipases and phospholipases |
| 05/31/2007 | CA2632090A1 Selected dosage for the treatment of cardiovascular and related pathologies |
| 05/31/2007 | CA2631017A1 Bisboron compounds for use as intracellular calcium concentration increase inhibitors |
| 05/31/2007 | CA2630551A1 N-hydroxyamide derivatives and use thereof |
| 05/31/2007 | CA2630049A1 Natural high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses |
| 05/31/2007 | CA2629935A1 (r)-arylalkylamino derivatives and pharmaceutical compositions containing them |
| 05/31/2007 | CA2629738A1 Novel indolizine derivatives, method for preparing same and therapeutic compositions comprising same |
| 05/31/2007 | CA2593718A1 Napthyridine compounds as rock inhibitors |
| 05/30/2007 | EP1790728A2 Imaging, diagnosis and treatment of disease |
| 05/30/2007 | EP1790717A2 Compositions and methods for the identification of lung tumor cells |
| 05/30/2007 | EP1790687A2 Cereal beta glucan compositions, methods of preparation and uses thereof |
| 05/30/2007 | EP1790655A2 Biologically active peptides |
| 05/30/2007 | EP1790652A1 Polycyclic guanine phosphodiesterase V inhibitors |
| 05/30/2007 | EP1790651A1 A1 adenosine receptor antagonists |
| 05/30/2007 | EP1790644A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |